


Case 21301P

Page 2

In the Claims

Claims 1-36 are canceled.

37(Currently Amended). A compound of Formula I



wherein

~~a and b are independently 0 or 1;~~

m is independently 0, 1 or 2;

R¹ is:

- 1) C₂-C₆ alkenyl,
- 2) C₂-C₆ alkynyl,
- 3) C₁-C₈ alkyl,
- 4) (C=O)NR^aR^b,
- 5) (C=O)R^c,
- 6) (C=O)OR^c, or
- 7) heterocyclyl, said heterocyclyl is substituted with at least one substituent selected from:
 - a) C₀-C₆ alkyl-(C=O)NR^aR^b,
 - b) C₀-C₆ alkyl-SO_mR^d,
 - c) C₀-C₆ alkyl-CO₂R^c,
 - d) C₁-C₆ alkyl-OR^c,
 - e) C₁-C₆ alkyl-NR^aR^b, and
 - f) C₀-C₆ alkyl-(C=O)-C₀-C₆ alkyl-OR^c;

R², R³ and R⁵ are hydrogen;R⁴ is selected from:

- 1) C₆-10 aryl,
- 2) C₅-10 heterocyclyl, provided that R⁴ is not pyrididonyl.

Case 21301P

Page 3

said aryl and heterocyclyl optionally substituted with at least one substituent selected from R^b;

R^a and R^b independently are independently selected from:

- 1) H,
- 2) C₁-C₆ alkyl,
- 3) C₂-C₆ alkenyl,
- 4) C₂-C₆ alkynyl,
- 5) C₃-C₁₀ cycloalkyl,
- 6) C₆-10 aryl,
- 7) C₅-10 heterocyclyl,
- 8) C₀-C₆ alkyl-(C=O)NR^aR^b,
- 9) C₀-C₆ alkyl-SO_mR^d,
- 10) C₀-C₆ alkyl-CO₂R^c,
- 11) C₀-C₆ alkyl-OR^c,
- 12) C₀-C₆ alkyl-NR^aR^b, and
- 13) C₀-C₆ alkyl-(C=O)-C₀-C₆ alkyl-OR^c,

said alkyl, aryl and heterocyclyl are optionally substituted with at least one substituent selected from R^d,

and wherein, when R^a and R^b are attached to a nitrogen within this definition, R^a and R^b are each independently selected from:

- a) H,
- b) unsubstituted or substituted C₁-C₆ alkyl,
- c) unsubstituted or substituted C₃-C₁₀ cycloalkyl;

R^c independently is:

- 1) H,
- 2) Unsubstituted or substituted C₁-C₆ alkyl,
- 3) Unsubstituted or substituted C₂-C₆ alkenyl,
- 4) Unsubstituted or substituted C₂-C₆ alkynyl,
- 5) Unsubstituted or substituted C₃-C₁₀ cycloalkyl,
- 6) Unsubstituted or substituted C₆-10 aryl, or
- 7) Unsubstituted or substituted C₅-10 heterocyclyl;

said substitution being at least one substituent selected from R^b;

Case 21301P

Page 4

R^d independently is:

- 1) Unsubstituted or substituted C₁-C₆ alkyl,
- 2) Unsubstituted or substituted C₂-C₆ alkenyl,
- 3) Unsubstituted or substituted C₂-C₆ alkynyl,
- 4) Unsubstituted or substituted C₃-C₁₀ cycloalkyl,
- 5) Unsubstituted or substituted C₆-10 aryl, or
- 6) Unsubstituted or substituted C₅-10 heterocyclyl;

said substitution being at least one substituent selected from R^b;

or a pharmaceutically acceptable salt or stereoisomer thereof.

38(Previously Presented). The compound of claim 37, wherein R⁴ is aryl, which is optionally substituted with at least one substituent selected from R^b; or a pharmaceutically acceptable salt or stereoisomer thereof.

39(Previously Presented). A compound selected from:


6-(4-methoxy-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester;
6-(4-methoxy-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid;
6-(4-methoxy-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid amide;
6-(4-methoxy-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carbonitrile;
ethyl 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]nicotinate;
5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-methylnicotinamide;
N-ethyl-5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]nicotinamide;
N-cyclopropyl-5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]nicotinamide;
5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-propylnicotinamide;
5-[6-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-methylnicotinamide;
N-ethyl-5-[6-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]nicotinamide;
5-[6-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-propylnicotinamide;
N-cyclopropyl-5-(6-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)nicotinamide;
N-propyl-5-(6-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)nicotinamide;

or a pharmaceutically acceptable salt or stereoisomer thereof.

40(Previously Presented). The compound according to claim 39 selected from:
5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-methylnicotinamide


Case 21301P

Page 5




or a pharmaceutically acceptable salt or stereoisomer thereof.

41(Previously Presented). The compound according to claim 39 selected from:
N-ethyl-5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]nicotinamide



or a pharmaceutically acceptable salt or stereoisomer thereof.

42(Previously Presented). The compound according to claim 39 selected from:
N-cyclopropyl-5-(6-pyridin-4-ylpyrazolo [1,5-a]pyrimidin-3-yl)nicotinamide



or a pharmaceutically acceptable salt or stereoisomer thereof.

43(Previously Presented). A pharmaceutical composition which is
comprised of a compound in accordance with claim 37 and a pharmaceutically acceptable
carrier.